Doxycycline or DOXY-PEP for STI prevention #shorts

A new study published in January 2025 found that rates of chlamydia and syphilis decreased among individuals prescribed doxycycline for sexually transmitted infection (STI) prevention in routine clinical care. In 2024, the CDC released guidelines recommending the use of doxycycline postexposure prophylaxis (DOXY-PEP) for STI prevention. This strategy involves taking a dose of doxycycline within 72 hours of sexual activity. Consider discussing DOXY-PEP with patients at high risk of STIs to help reduce their risk and improve their sexual health. While there are important questions still to be addressed—such as the potential effects of doxycycline on antimicrobial resistance—current evidence highlights its significant benefits in reducing STI transmission.